<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01947140</url>
  </required_header>
  <id_info>
    <org_study_id>AAAJ5656</org_study_id>
    <nct_id>NCT01947140</nct_id>
  </id_info>
  <brief_title>Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies</brief_title>
  <acronym>PDX+Romi</acronym>
  <official_title>Phase I/IIA Study of the Novel Antifolate Agent Pralatrexate in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies and Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jennifer Amengual</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to test how safe the combination of the drugs Romidepsin and Pralatrexate are
      in patients with lymphoid malignancies and to determine the dose of the combination of drugs
      that is safest. If the combination is determined to be safe, the study will continue accrual
      patients with peripheral T-Cell lymphoma (PTCL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The non- Hodgkin lymphomas (NHL) represent a heterogeneous group of malignancies. Under the
      rubric of lymphoma exist some of the fastest growing cancers known to science, (Burkett's
      lymphoma, lymphoblastic lymphoma/leukemia), as well as some of the most indolent (small
      lymphocytic lymphoma, follicular lymphoma, and marginal zone lymphoma). This remarkable
      diversity of biology imposes significant challenges. Researchers are seeking to understand
      the cell of origin and differentiate what are sometimes subtle differences between the
      related sub-types of disease; and to identify the best treatments for these subtypes, with
      the ever-increasing likelihood that new understanding of the molecular pathogenesis of these
      diseases will result in an increase in new drugs for specific target populations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of the combination of pralatrexate and romidepsin</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>For Phase I</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR) (complete + partial response) of the combination of pralatrexate and romidepsin in patients with relapsed/refractory T-Cell Lymphoma</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>For Phase II</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum number of cycles received</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>For Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dose delays at the MTD</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>For Phase I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) of the study population</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>For Phase I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) of the combination in patients with T-Cell Lymphoma</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>For Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) of patients with T-Cell Lymphoma on study</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>For Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) of the combination in patients with T-Cell Lymphoma</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>For Phase II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dose reductions at the MTD</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>For Phase I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) of the study population</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>For Phase I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) of the study population.</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>For Phase I</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Lymphoid Malignancies</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Non-hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase I: Schedule A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 8 of each 21 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: Schedule B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive dose escalation of pralatrexate and romidepsin, receiving both infusions on days 1 and 15 of each 28 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Pralatrexate 25 mg/m2 and Romidepsin 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pralatrexate</intervention_name>
    <description>Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 10 mg/m2 to 25 mg/m2
Phase II - 25 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle.</description>
    <arm_group_label>Phase I: Schedule A</arm_group_label>
    <arm_group_label>Phase I: Schedule B</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Folotyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romidepsin</intervention_name>
    <description>Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 12 mg/m2 to 14 mg/m2.
Phase II - 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle.</description>
    <arm_group_label>Phase I: Schedule A</arm_group_label>
    <arm_group_label>Phase I: Schedule B</arm_group_label>
    <arm_group_label>Phase II</arm_group_label>
    <other_name>Istodax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Phase I: Patients must have histologically confirmed relapsed or refractory Non-Hodgkin's
        lymphoma, Hodgkin's Disease or multiple myeloma (defined by World Health Organization (WHO)
        criteria).

        Phase II: Patients must have histologically confirmed relapsed or refractory T-Cell
        Lymphoma (as defined by WHO criteria).

          -  Must have received first line chemotherapy. No upper limit for the number of prior
             therapies

          -  Evaluable Disease

          -  Age ≥18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2

          -  Patients must have adequate organ and marrow function as defined in the protocol

          -  Adequate Contraception

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Inclusion Criteria for Multiple Myeloma patients specified in the protocol

        Exclusion Criteria:

          -  Prior Therapy

               -  Exposure to chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosureas
                  or mitomycin C) prior to entering the study or those who have not recovered from
                  adverse events due to agents administered more than 2 weeks earlier

               -  Systemic steroids that have not been stabilized to the equivalent of ≤10 mg/day
                  prednisone prior to the start of the study drugs

               -  No other investigational agents are allowed

          -  Central nervous system metastases, including lymphomatous meningitis

          -  History of allergic reactions to Pralatrexate or Romidepsin

          -  Uncontrolled intercurrent illness

          -  Pregnant women

          -  Nursing women

          -  Current malignancy or history of a prior malignancy, as outlined in the protocol

          -  Patient known to be Human Immunodeficiency Virus (HIV)-positive

          -  Active Hepatitis A, Hepatitis B, or Hepatitis C infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer E Amengual, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renee Lichtenstein</last_name>
    <phone>212-326-5720</phone>
    <email>rl2619@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Lichtenstein</last_name>
      <phone>212-326-5720</phone>
      <email>rl2619@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer E Amengual, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2013</study_first_submitted>
  <study_first_submitted_qc>September 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2013</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Jennifer Amengual</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine &amp; Experimental Therapeutics</investigator_title>
  </responsible_party>
  <keyword>Lymphoid Malignancies</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Hodgkin Lymphoma</keyword>
  <keyword>Non-hodgkin Lymphoma</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Anaplastic Large Cell Lymphoma</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Small Lymphocytic Lymphoma</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>Marginal Zone Lymphoma</keyword>
  <keyword>Burkitt Lymphoma</keyword>
  <keyword>Waldenstrom Macroglobulinemia</keyword>
  <keyword>Peripheral T-cell Lymphoma</keyword>
  <keyword>Cutaneous T-cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
    <mesh_term>Aminopterin</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

